Wondering about your take on the CC. Mine is fairly positive as PTN is probably going to run two PH III trials (EU and USA). They're fairly certain about the market in the EU and revenues (if approved) that they'll get through the licensing agreement with the 'major pharma provider in the EU that is strong in female drugs category.' Any comments, Phil?
I haven't gone anywhere. In fact, I bought some more stock at 59 cents a few days ago. I haven't been posting lately because I was so angry that the FDA has put them at least three months behind schedule because of that silly trial to test the delivery system. I can't see how this was necessary..
The patent news is good. This may have what has been holding up a partnership agreement on the asthma drug. It is also encouraging that they received a good faith deposit on European rights to market BMT for premenopausal women. I wonder if this is a German company that developed Filbaseren.
It appears that we are still waiting on final approval of protocols from the FDA. This could be the last hurdle before launching phase3 with a major partner. When that happens, the stock will fly.
The "stock will fly" but it will take a long taxi-way and runway to get there. I was wondering about the protocols for PH III testing in the EU... is it more or less stringent than in the US? The company's fate teeters on the answer. I'm still optimistic on PTN